Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00171223 · ClinicalTrials.gov registry record · Phase 2
An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 532
- Enrollment target
NCT00171223 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 532 participants.
The verdict
NCT00171223, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 532 participants
- Enrollment target
Study Summary
During the Core Phase of the study, participants received STI571 at a dose of 400 milligrams (mg) daily for up to 12 months. Participants completing 12 months of therapy were eligible to continue treatment in the Extension Phase of the study provided that, in the opinion of the investigator, they had benefited from treatment with STI571 and there were no safety concerns.
Interventions
- DRUG STI571
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 532 participants |
| Start Date | 1999-12-06 |
| Est. Completion | 2013-11-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00171223
The ClinicalTrials.gov registry entry for NCT00171223 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 532 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which STI571 is the first listed.
NCT00171223 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00171223 about?
NCT00171223 is a clinical study titled "An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha". During the Core Phase of the study, participants received STI571 at a dose of 400 milligrams (mg) daily for up to 12 months. Participants completing 12 months of therapy were eligible to continue treatment in the Extension Phase of the study provided that, in the opinion of the investigator, they ha...
What is the current status of trial NCT00171223?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 532 participants. The study started on 1999-12-06. Estimated completion is 2013-11-29.
What interventions are being tested in trial NCT00171223?
The interventions under investigation include: STI571 (DRUG).
Who is sponsoring clinical trial NCT00171223?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.